GREENLAND MINES LTD Interest Expense Nonoperating
GREENLAND MINES LTD (GRML) reported Interest Expense Nonoperating of $4.89 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-17
- GREENLAND MINES LTD interest expense nonoperating for the quarter ending 2026-06-30 was $4.89K, a 99.72% decline year-over-year.
- GREENLAND MINES LTD interest expense nonoperating for the quarter ending 2026-03-31 was $1.61K, a 99.71% decline year-over-year.
- GREENLAND MINES LTD interest expense nonoperating for the quarter ending 2025-12-31 was -$1.18M, a 497.19% decline year-over-year.
- GREENLAND MINES LTD interest expense nonoperating for the quarter ending 2025-09-30 was $1.18M, a 2520.34% increase year-over-year.
- GREENLAND MINES LTD interest expense nonoperating for fiscal 2025 was $2.31M, a 548.89% increase from fiscal 2024.
- GREENLAND MINES LTD interest expense nonoperating for fiscal 2024 was $356.60K, a 367.90% increase from fiscal 2023.
- GREENLAND MINES LTD interest expense nonoperating for fiscal 2023 was $76.21K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.89K 10-Q · filed 2026-08-17 | $6.50K 10-Q · filed 2026-08-17 | -$1.17M derived: sum of 3 quarters · filed 2026-08-17 | $6.50K derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $1.61K 10-Q/A · filed 2026-08-14 | -$1.18M derived: sum of 2 quarters · filed 2026-08-14 | $1.61K derived: sum of 3 quarters · filed 2026-08-14 | $1.76M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | -$1.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$1.00 derived: sum of 2 quarters · filed 2026-08-14 | $1.76M derived: sum of 3 quarters · filed 2026-08-17 | $2.31M 10-K/A · filed 2026-08-14 |
| 2025-09-30 | $1.18M 10-Q · filed 2025-11-13 | $2.94M derived: sum of 2 quarters · filed 2026-08-17 | $3.49M 10-Q · filed 2025-11-13 | $3.79M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $1.76M 10-Q · filed 2026-08-17 | $2.31M 10-Q · filed 2026-08-17 | $2.61M derived: sum of 3 quarters · filed 2026-08-17 | $2.66M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $553.94K 10-Q/A · filed 2026-08-14 | $850.52K derived: sum of 2 quarters · filed 2026-08-14 | $895.48K derived: sum of 3 quarters · filed 2026-08-14 | $910.54K derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | $296.58K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $341.54K derived: sum of 2 quarters · filed 2026-08-14 | $356.60K derived: sum of 3 quarters · filed 2026-08-14 | $356.60K 10-K/A · filed 2026-08-14 |
| 2024-09-30 | $44.96K 10-Q · filed 2025-11-13 | $60.02K derived: sum of 2 quarters · filed 2025-11-13 | $60.02K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $15.06K 10-Q · filed 2025-08-18 | $15.06K 10-Q · filed 2025-08-18 | ||
| 2023-12-31 | $15.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $36.12K derived: sum of 2 quarters · filed 2025-03-31 | $56.28K derived: sum of 3 quarters · filed 2025-03-31 | $76.21K 10-K · filed 2025-03-31 |
| 2023-09-30 | $20.38K 10-Q · filed 2024-11-19 | $40.54K derived: sum of 2 quarters · filed 2024-11-19 | $60.47K 10-Q · filed 2024-11-19 | |
| 2023-06-30 | $20.16K 10-Q · filed 2024-08-19 | $40.09K 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |